Drug Trial Radar · NCT05142722
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,530
Actual
Start
Dec 15, 2021
Primary completion
Sep 26, 2024
Study completion Sep 26, 2024
Sponsor
- Lead sponsor
- NewAmsterdam PharmaIndustry
- Sponsor type
- Industry
- First posted
- Dec 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy
Conditions
- Dyslipidemias
- High Cholesterol
- Hypercholesterolemia
- Familial Hypercholesterolemia
- Atherosclerotic Cardiovascular Disease
Interventions
PlaceboDrug
placebo tablet made to resemble active
ObicetrapibDrug
10mg obicetrapib tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC]Time frame: 84 Days
Locations
181 sites in 8 countries. Site status is shown where the registry gives one.
Pinnacle Research Group
Anniston, Alabama
Central Alabama Research
Birmingham, Alabama
Synexus Clinical Research US, Inc. / Simon Williamson Clinic, PC
Birmingham, Alabama
The Center for Clinical Trials, Inc
Saraland, Alabama
Syed Research Consultants, LLC
Sheffield, Alabama
Clinical Research Institute of Arizona, LLC
Sun City West, Arizona
Synexus Clinical Research US, Inc. / Orange Grove Family Practice
Tucson, Arizona
Eclipse Clinical Research
Tucson, Arizona
American Institute of Research
Beverly Hills, California
Orange County Research Center
Tustin, California
Synexus Clinical Research US, Inc.
Vista, California
Excel Medical Clinical Trials
Boca Raton, Florida
Pioneer Clinical Studies
Ft. Pierce, Florida
New Generation of Medical Research
Hialeah, Florida
East Coast Institute for Research, LLC
Jacksonville, Florida
East Coast Institute for Research, LLC - Jacksonville University Blvd
Jacksonville, Florida
East Coast Institute for Research- Lake City
Lake City, Florida
ClinCloud LLC
Maitland, Florida
Columbus Clinical Services, LLC
Miami, Florida
Kendall South Medical Center, Inc.
Miami, Florida
Advanced Research Institute Inc
New Port Richey, Florida
Progressive Medical Research
Port Orange, Florida
East Coast Institute for Research
Saint Augustine, Florida
Synexus Clinical Research US, Inc.
The Villages, Florida
Synexus Clinical Research US, Inc.
Atlanta, Georgia
East Coast Institute for Research - Canton
Canton, Georgia
Centricity Research
Columbus, Georgia
East Coast Institute for Research, LLC
Macon, Georgia
Alta Pharmaceutical Research Center
Peachtree Corners, Georgia
SouthCoast Health
Savannah, Georgia
Biofortis, Inc
Addison, Illinois
Evanston Premier Healthcare Research LLC
Skokie, Illinois
Synexus Clinical Research US, Inc.
Evansville, Indiana
Midwest Institute for Clinical Research
Indianapolis, Indiana
Cotton-O'Neil Clinical Research Center
Topeka, Kansas
Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
Louisville, Kentucky
Research Integrity, LLC
Owensboro, Kentucky
Cambridge Medical Trials
Alexandria, Louisiana
Grace Research, LLC
Bossier City, Louisiana
Tandem Clinical Research
Marrero, Louisiana
Showing 40 of 181 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.